Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



AstraZeneca to Acquire Omthera Pharma

AstraZeneca (NYSE: AZN  ) will pay shareholders of Omthera Pharmaceuticals (UNKNOWN: OMTH.DL  ) $12.70 a share, valuing the drugmaker at approximately $323 million, in an acquisition deal announced today.

Less Omthera's existing cash and equivalents of $63 million, the enterprise value of the deal is approximately $260 million, according to AstraZeneca. However, if certain conditions are met, Omthera shareholders are in line for up to $120 million more.

Omthera has completed two phase 3 trials for Epanova, and reported success in lowering test subjects' high triglyceride and, in combination with a statin, HDL cholesterol levels. AstraZeneca CEO Pascal Soriot commented, "The number of people with elevated triglyceride levels is rising rapidly across the world, due in part to the increasing prevalence of obesity and diabetes." Soriot added "This is an exciting acquisition that clearly complements our existing portfolio in cardiovascular and metabolic disease, one of our core therapy areas." The company expects a New Drug Application to be filed in the U.S. by mid-2013.

Omthera shareholders will receive contingent value rights (CVRs) up to an estimated $4.70 a share, for a total of $120 million, if certain milestones relating to Epanova are met. If the conditions for Epanova are reached, the total value of the acquisition would be an estimated $443 million.

The boards of directors of both AstraZeneca and Omthera have unanimously agreed to the deal, and assuming approval of Omthera shareholders and meeting customary regulatory conditions, the acquisition is expected to close the third quarter of 2013.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2455521, ~/Articles/ArticleHandler.aspx, 9/27/2016 11:39:37 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,145.85 51.02 0.28%
S&P 500 2,152.22 6.12 0.29%
NASD 5,281.65 24.16 0.46%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/27/2016 11:23 AM
AZN $33.31 Down -0.24 -0.72%
AstraZeneca CAPS Rating: ****